key: cord-0890393-io0cqgs8
authors: Alizargar, Javad
title: Dangers of the Use of hydroxychloroquine and azithromycin combination in COVID-19 patients
date: 2020-09-18
journal: Travel Med Infect Dis
DOI: 10.1016/j.tmaid.2020.101881
sha: 56fcedaac3a0744aa13fba7fffbe8f4049307019
doc_id: 890393
cord_uid: io0cqgs8

nan

Gautret et al. [1] in an observational study showed that the combination of hydroxychloroquine and azithromycin could be beneficial in COVID-19 patients. Although the results in these 80 patients were satisfactory, more studies needed to evaluate the risks versus benefits in these patients. Some studies report the beneficial effects of these combination of drugs in treating COVID-19 patients. In a retrospectively report on 1061 patients, Million et al. [2] reported that this combination is effective in the COVID-patients before COVID-19 complications occur. In some studies, no clinical benefit or evidence of a strong antiviral activity was observed in COVID-19 patients by using this combination of drugs. A study by Rosenberg et al. [3] on 1438 COVID-19 patients, no significant result associated with the use of this combination of drugs was reported. While there is still strong disagreement between many studies reporting the beneficial effects of this combination in the treatment of COVID-19 patients, with a lack of large randomized control trial, special attention needs to be drawn on the complications that the use of these drugs might impose to the patients and public health.

One of the complications on the patients that needs to be addressed is the QT interval prolongation. Both hydroxychloroquine, an anti-malarial drug for arthritis and systemic lupus erythematosus treatment and Azithromycin, a broad-spectrum macrolide, have confirmed complication of prolongation of QT interval by blocking cardiac potassium channel, and increase the risk of fatal torsades des pointes. The use of the combination of these two drugs in COVID-19 patients is reported to critically prolong QTc in up to 23% of the patients [4] .

The other important complication that the use of this combination of drugs might impose to the public health is the antibiotic resistance caused by the excessive use of Azithromycin. Antibiotic resistance can be considered an important issue if we think about the abundant cases of COVID-19 in this pandemic, and the use of antibiotics to fight the coinfection of bacterial species with the coronavirus [5] . Moreover, COVID-19 epidemics make a shift from face-to-face clinic visits to telehealth consultations, which have been shown to be associated with higher antibiotic usage [6] .

As per conclusion, using new drugs should be fully studies before the wide usage in the course of pandemics. Using the combination of hydroxychloroquine and azithromycin should be proven to be effective first, and the short-term and long-term risks and benefits should be studies in details before advertising these treatments. Hastily use of hydroxychloroquine and azithromycin combination to get rid of the burden of COVID-19 might cause bigger problems with bigger burdens.

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study

Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State

QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin. Hear Rhythm

Co-infection with respiratory pathogens among COVID-2019 cases

How covid-19 is accelerating the threat of antimicrobial resistance